| Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 KJ Mavrakis, ER McDonald III, MR Schlabach, E Billy, GR Hoffman, ... Science 351 (6278), 1208-1213, 2016 | 491 | 2016 |
| Suppression of in vivo β-amyloid peptide toxicity by overexpression of the HSP-16.2 small chaperone protein V Fonte, DR Kipp, J Yerg, D Merin, M Forrestal, E Wagner, CM Roberts, ... Journal of Biological Chemistry 283 (2), 784-791, 2008 | 194 | 2008 |
| ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor Z Mounir, JM Korn, T Westerling, F Lin, CA Kirby, M Schirle, G McAllister, ... Elife 5, e13964, 2016 | 85 | 2016 |
| Mass-dependent bond vibrational dynamics influence catalysis by HIV-1 protease DR Kipp, RG Silva, VL Schramm Journal of the American Chemical Society 133 (48), 19358-19361, 2011 | 78 | 2011 |
| The novolactone natural product disrupts the allosteric regulation of Hsp70 AQ Hassan, CA Kirby, W Zhou, T Schuhmann, R Kityk, DR Kipp, J Baird, ... Chemistry & biology 22 (1), 87-97, 2015 | 55 | 2015 |
| Transition states of native and drug-resistant HIV-1 protease are the same DR Kipp, JS Hirschi, A Wakata, H Goldstein, VL Schramm Proceedings of the National Academy of Sciences 109 (17), 6543-6548, 2012 | 33 | 2012 |
| Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia A Varkaris, E Pazolli, H Gunaydin, Q Wang, L Pierce, AA Boezio, A Bulku, ... Cancer Discovery 14 (2), 240-257, 2024 | 29 | 2024 |
| Enzyme-dependent lysine deprotonation in EZH2 catalysis DR Kipp, CM Quinn, PD Fortin Biochemistry 52 (39), 6866-6878, 2013 | 28 | 2013 |
| Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors AM Taylor, BR Williams, F Giordanetto, EH Kelley, A Lescarbeau, ... Journal of Medicinal Chemistry 66 (19), 13384-13399, 2023 | 21 | 2023 |
| Constrained Bonding Environment in the Michaelis Complex of Trypanosoma cruzi Uridine Phosphorylase RG Silva, DR Kipp, VL Schramm Biochemistry 51 (34), 6715-6717, 2012 | 9 | 2012 |
| Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors B Williams, A Taylor, O Orozco, C Owen, E Kelley, A Lescarbeau, ... Cancer Research 82 (12_Supplement), 3327-3327, 2022 | 7 | 2022 |
| Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα E Pazolli, R Kipp, GH BA, A Iskandar, M Zubrowski Mol Cancer Ther 20 (12 Suppl), P251, 2021 | 6 | 2021 |
| RLY-2608: the first allosteric mutant-and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care … E Pazolli, R Kipp, A Boezio, H Gunaydin, A Iskandar, M Zubrowski, ... Cancer Res. 82, 2022 | 2 | 2022 |
| Abstract LB-017: disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5 K Mavrakis, ER McDonald III, MR Schlabach, E Billy, GR Hoffman, ... Cancer Research 76 (14_Supplement), LB-017-LB-017, 2016 | 1 | 2016 |
| Abstract P5-16-10: RLY-2608: The first allosteric mutant-and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with … E Pazolli, R Kipp, A Boezio, H Gunaydin, A Iskandar, M Zubrowski, ... Cancer Research 82 (4_Supplement), P5-16-10-P5-16-10, 2022 | | 2022 |
| Conformation-selective inhibitors stabilize SRC in the globally closed conformation and are active in pre-clinical models of IDH mutant intrahepatic cholangiocarcinoma J Casaletto, J Wilbur, B Toure, B Williams, M Zubrowski, ... EUROPEAN JOURNAL OF CANCER 103, E133-E133, 2018 | | 2018 |
| Hiv-1 protease transition state and uses thereof VL Schramm, DR KIPP, JS HIRSCHI | | 2013 |
| Electrostatic Potential Analysis of FDA Approved HIV-1 Protease Inhibitors DR Kipp, VL Schramm UMT, 95, 2012 | | 2012 |
| Introduction: Transition States and Dynamics of HIV-1 Protease DR Kipp, VL Schramm UMT, 1, 2012 | | 2012 |
| Conclusions, Significance, And Future Directions: Transition States and Dynamics of HIV-1 Protease DR Kipp, JS Hirschi, RG Silva, A Wakata, H Goldsteinb, VL Schramm UMT, 115, 2012 | | 2012 |
